Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GNG2 | P59768 | 1/20 | 0.42 |
| ▸ | GNB1 | P62873 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726590 | 0.84 | GSK3B (0.61) | GSK3BPTPN1 | |
| SCHEMBL30187429 | 0.84 | GSK3B (0.61) | GSK3BPTPN1 | |
| SCHEMBL5186624 | 0.82 | ALDH1A1 (0.54) | ESR1ESR2TP53TDP1ESRRG | |
| SCHEMBL1259916 | 0.82 | ESRRG (0.46) | ESR1ESR2TP53TDP1ESRRG | |
| SCHEMBL8343669 | 0.82 | PTPN1 (0.59) | GSK3BPTPN1 | |
| SCHEMBL883208 | 0.81 | GSK3B (0.57) | GSK3BPTPN1GNG2GNB1 | |
| SCHEMBL9908793 | 0.81 | GSK3B (0.48) | GSK3BESR1ESR2TP53TDP1 | |
| SCHEMBL12949980 | 0.81 | HSD17B3 (0.50) | ESR1ESR2TP53TDP1ESRRG | |
| SCHEMBL7620529 | 0.79 | GSK3B (0.55) | GSK3BPTPN1GNG2GNB1 | |
| SCHEMBL16056966 | 0.79 | GSK3B (0.55) | GSK3BPTPN1GNG2GNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017168431-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-05 | — | — | WO | disclosed |
| EP-1506195-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1506195-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-6806265-B2 | FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2004-01-08 | — | — | US | disclosed |
| WO-2003097644-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
| US-6489337-B1 | TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-03 | — | — | US | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | CBR1, POLR2H, SUB1 | GSK3B 4284/4885PTPN1 1988/4885ESR1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.